Intravenous versus intracoronary bolus of glycoprotein IIb/IIIa inhibitor administration during primary percutaneous coronary intervention on long-term left ventricular systolic and diastolic function

Pierpaolo Pellicori, Concetta Torromeo, Francesco Barillà, Enrico Mangieri, Antonietta Evangelista, Giovanni Truscelli, Pierluigi Costanzo, Angela Hoye, Kenneth Wong
2013 Cardiology Journal  
In primary percutaneous coronary intervention (PCI), glycoprotein (GP) IIb/IIIa inhibitors are often given in order to attain and maintain better myocardial perfusion. We tested the hypothesis that intracoronary (IC) bolus of GP IIb/IIIa inhibitors might produce a greater improvement in left ventricular (LV) systolic and diastolic function than an intravenous (IV) bolus. Methods and results: Seventy seven patients undergoing primary PCI for their first ST elevation myocardial infarction (STEMI)
more » ... infarction (STEMI) were randomly assigned to either an IC or IV bolus of GP IIb/IIIa inhibitor, followed by IV infusion. Compared with the echocardiographic findings within 3 days after PCI, LV ejection fraction was higher at 1 year, with no significant differences between the IV and IC groups (IV: 44% vs. 49%, p = 0.001; IC: 43% vs. 48%, p < 0.001). LV diastolic function (E/E') did not significantly change at 1 year by either approach. Conclusions: LV systolic function improved by a similar magnitude following primary PCI, with either IC or IV bolus administration of GP IIb/IIIa inhibitor therapy. However, no significant changes were observed in LV diastolic function. (Cardiol J 2013; 20, 3: 310-317)
doi:10.5603/cj.2013.0077 pmid:23788306 fatcat:vh55se3fhncdlbm6outjvwqt2u